Researchers have found that inhibiting the S6K2 gene could be an effective strategy for managing treatment-resistant melanoma, according to a recent study published by Lipchick et al in Science Translational Medicine.
Of Interest
Over a quarter of stem cell transplant survivors develop cutaneous malignant neoplasms
More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.
Dr Ascierto on First-Line Treatment Selection in Advanced BRAF+ Melanoma
Paolo A. Ascierto, MD, director, Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses treatment sequencing considerations for patients with advanced BRAF-mutant melanoma, based on findings from the phase 2 SECOMBIT (NCT02631447) and phase 3 DREAMseq (NCT02224781) trials.
Dr Robert on the Role of Adjuvant Anti–PD-1 Therapy in Resected Stage IIB/C Melanoma
Caroline Robert, MD, PhD, head, Dermatology Unit, Gustave Roussy, discusses the role of adjuvant anti–PD-1 therapy in the treatment of patients with resected stage IIB/C melanoma, highlighting findings from the phase 3 KEYNOTE-716 (NCT03553836) and CheckMate 76K (NCT04099251) trials that have informed treatment decisions in this setting.